Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01189123 · ClinicalTrials.gov registry record · NA
Cell Mediated Immunity in Older Adults
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 105
- Enrollment target
NCT01189123 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 105 participants.
The verdict
NCT01189123, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 105 participants
- Enrollment target
Study Summary
This study is to study the immune response to the flu vaccine in people 65 years old and older. Only adults 65 years old and older and who are getting their flu vaccine are being asked to join in this study. The investigators plan to enroll approximately 100 people in this study in the 2010-2011 flu season. Vanderbilt is working with the Centers for Disease Control and Prevention on this study. There will be 5 study visits. Up to 4 tablespoons of blood from a vein will be obtained prior to the flu shot. Return visits will be 1, 2, and 4 weeks later,with up to 4 tablespoons of blood drawn again. Patients will be randomized to receive either the standard dose or the high dose flu vaccine. Both flu vaccines are FDA-approved.
Interventions
- BIOLOGICAL High dose influenza vaccine Sanofi-Pasteur
- BIOLOGICAL fluzone by sanofi pasteur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01189123
The ClinicalTrials.gov registry entry for NCT01189123 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which High dose influenza vaccine Sanofi-Pasteur is the first listed.
NCT01189123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01189123 about?
NCT01189123 is a clinical study titled "Cell Mediated Immunity in Older Adults". This study is to study the immune response to the flu vaccine in people 65 years old and older. Only adults 65 years old and older and who are getting their flu vaccine are being asked to join in this study. The investigators plan to enroll approximately 100 people in this study in the 2010-2011 flu...
What is the current status of trial NCT01189123?
This trial is currently completed. It is a NA study. The enrollment target is 105 participants. The study started on 2010-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01189123?
The interventions under investigation include: High dose influenza vaccine Sanofi-Pasteur (BIOLOGICAL), fluzone by sanofi pasteur (BIOLOGICAL).
Who is sponsoring clinical trial NCT01189123?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.